Clinical trials: copd or chronic obstructive
COPD
A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world.
- Trial name
- NCT01794780
- Testing
- LABA based treatment: indacaterol, LAMA based treatment: tiotropium, LABA/ICS based treatment: salmeterol/fluticasone
- Where
- 2 sites in China
- Volunteers
- 2,229 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in…
- Trial name
- NCT01572792
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate
- Where
- 208 sites in United States, Australia and 2 more
- Volunteers
- 921 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example
Documentation of successful therapy with tiotropium (Spiriva Respimat; Spiriva (tiotropium 18 mcg capsules)) in COPD patients requiring long-acting bronchodilators: description of the most important outcome parameters according…
- Trial name
- NCT01036763
- Where
- 352 sites in Germany
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with…
- Trial name
- NCT01323621
- Testing
- Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Salbutamol as needed
- Where
- 51 sites in United States, Germany and 4 more
- Volunteers
- 512 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease COPD
Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This is a phase IIIb randomised, double-blind, double-dummy, multicentre, parallel group, 24 week study to assess the efficacy and safety of Glycopyrronium/Formoterol Fumarate (GFF) fixed-dose combination 7.2/4.8 μg 2 inhalations…
- Trial name
- AERISTO (NCT03162055)
- Testing
- Glycopyrronium/Formoterol Fumarate, umeclidinium/vilanterol
- Where
- 107 sites in United States, Bulgaria and 5 more
- Volunteers
- 1,119 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
The purpose of the study is to investigate the effect of fluticasone furoate/vilanterol Inhalation Powder on arterial stiffness compared with placebo and vilanterol over a 24-week treatment period in subjects with COPD and aortic…
- Trial name
- NCT01336608
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 72 sites in United States, Germany and 4 more
- Volunteers
- 446 people
- Sponsor
- GlaxoSmithKline
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with…
- Conditions
- Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05660850
- Testing
- GDC-6599, Mannitol
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Chronic Graft Versus Host Disease, Fasciitis
Glasdegib for Chronic Graft-Versus-Host Disease
This phase I/II trial studies whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease.
- Trial name
- NCT04111497
- Testing
- Glasdegib
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Fred Hutchinson Cancer Center
COPD Exacerbation
Acupuncture Treatment of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Chronic obstructive pulmonary disease (COPD) is a major health problem. Acute exacerbations are a health-care burden involving frequent hospitalizations and elevated costs.
- Trial name
- NCT03398213
- Testing
- Acupuncture
- Where
- 2 sites in Israel
- Volunteers
- 72 people
- Sponsor
- Bnai Zion Medical Center
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo.
- Trial name
- NCT01669174
- Testing
- BYM338
- Where
- 9 sites in United States, Netherlands and 1 more
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
SMS Reminder to Assess Adherence
6 months open label non-interventional observational study acc to § 4, section 23 and § 67, section 6 German Medicines Act with two parallel groups 1.
- Trial name
- NCT01308476
- Testing
- SMS reminder, control group
- Where
- 5 sites in Germany
- Volunteers
- 95 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
HHHFA in COPD Patients, With Chronic Bronchitis
Heated, humidified high-flow air (HHHFA) devices improve airway clearance. HHHFA use for an average of 1.6 hours a day in COPD patients with chronic bronchitis improves health-related quality of life, lung function, and delays…
- Trial name
- NCT03959982
- Testing
- HHHFA Device, Spirometry, 6-minute walk
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Spyridon Fortis
Pulmonary Disease, Chronic Obstructive
Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
The aim of the study is to investigate whether the early introduction of maintenance bronchodilator therapy during an acute symptomatic episode of the disease shows benefits on the recovery of symptoms.
- Trial name
- NCT01483625
- Testing
- tiotropium
- Where
- 27 sites in United States
- Volunteers
- 140 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy
To assess the comparative effectiveness of combination Tiotropium and Olodaterol (Tio+Olo) (FDC) compared to combination LAMA/LABA and ICS (fixed or open), and to explore whether this varies across COPD sub populations defined by…
- Trial name
- NCT04184297
- Testing
- Tiotropium and Olodaterol (Tio+Olo), Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
- Where
- United States
- Volunteers
- 27,190 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients
The primary objective of this study is to assess the pharmacokinetics of tiotropium + olodaterol fixed-dose combination (FDC) (5 μg/ 5 μg) delivered by the RESPIMAT inhaler after single dose and at steady state in Chinese…
- Trial name
- NCT02969317
- Testing
- Tiotropium, Olodaterol
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Re-usable Respimat® Soft MistTM Inhaler Study
The study is to assess patient satisfaction with the inhaler attributes of the re-usable Respimat SMI (Spiriva, Striverdi or Spiolto) in patients with COPD, including patients who are Respimat SMI-experienced and Respimat…
- Trial name
- NCT04011735
- Testing
- Respimat
- Where
- 20 sites in Belgium, Denmark and 4 more
- Volunteers
- 262 people
- Sponsor
- Boehringer Ingelheim
Asthma, Chronic Obstructive Pulmonary Disease
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic…
- Trial name
- NCT05292950
- Testing
- ARO-MUC5AC
- Where
- 13 sites in Australia, New Zealand and 5 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)
The inflammation associated with COPD is characterized by a prominent infiltration of neutrophils in lung tissue and airways. The CXC chemokine receptor type 2 (CXCR2) plays a pivotal role in neutrophil recruitment to the lungs…
- Trial name
- NCT03250689
- Testing
- Danirixin, Rescue medication, Inhaled COPD maintenance medication
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Alpha-1 Antitrypsin Deficiency, Emphysema
Alpha-1 Carrier Genomics Study
The goal of this study is to better understand why some Alpha-1 genotype MZ (PiMZ) individuals develop chronic obstructive pulmonary disease (COPD) while others do not.
- Conditions
- Alpha-1 Antitrypsin Deficiency, Emphysema, COPD, Smoking
- Trial name
- NCT02810327
- Testing
- Genetic Sequencing
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Medical University of South Carolina
Chronic Obstructive Pulmonary Disease (COPD)
The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to investigate effects of inhaled AZD8683 compared to placebo in COPD patients.
- Trial name
- NCT01205269
- Testing
- AZD8683, 50 mcg, AZD8683, 200 mcg
- Where
- 4 sites in Poland
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.